A Phase 2 interventional study of Placebo Cream and Ruxolitinib Phosphate Cream in Alopecia Areata, sponsored by Incyte Corporation. Terminated at 18 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-16.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.
Among the 98 studies in Alopecia Areata with a site in United States, this one is the 24th largest by enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2015, is one of 42 in phase 2, and was the 25th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Japan and 1 more country
Ages 6–17
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18–60
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Almirall, S.A. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 48 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 46 across the 84 interventional studies, 2,300 across the 14 observational. Of the 60 that completed or were terminated, 42 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 1 study filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
10 of the studies in Alopecia Areata with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
| NCT06826196Aldena TherapeuticsA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | 2026-11 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 98 studies in Alopecia Areata with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks; Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks.
Drug: Ruxolitinib Phosphate Cream
Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
Drug: Placebo Cream · Drug: Ruxolitinib Phosphate Cream
Also known as: INCB018424
Part A: Percentage of Participants Achieving a ≥ 50% Improvement in SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).
Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.
Time frame: Up to Week 24
Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented)
Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.
Time frame: Week 24
Part A : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair.
Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.
Time frame: Up to Week 24
Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented).
Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.
Time frame: Week 24
Part A and B : Percentage of Participants Achieving a SALT90 Response in Terminal Hair.
Number of participants achieving 90% or greater improvement in their SALT score (SALT90) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.
Time frame: Weeks 4, 8, 12, 18, and 24.
Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3
Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, \<25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).
Time frame: Baseline to Week 24
Part B : Percentage of Participants Achieving a SALT50 in Terminal Hair (Pigmented and Nonpigmented).
Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes
Time frame: Weeks 4, 8, 12, and 18.
Part B: Mean Change From Baseline in SALT Score
Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).
Time frame: Weeks 4, 8, 12, 18, and 24.
Part A and B : Number of Treatment-emergent Adverse Events
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment
Time frame: Up to 100 weeks
This study was conducted at 17 study centers in the United States.
| Milestone | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|---|
| Started | 12 | 39 | 39 |
| Completed | 7 | 0 | 2 |
| Not completed | 5 | 39 | 37 |
| Withdrew: Study terminated by sponsor | 2 | 13 | 12 |
| Withdrew: Withdrawal by subject | 3 | 19 | 21 |
| Withdrew: Other | 0 | 1 | 0 |
| Withdrew: Non compliance to study treatment | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 4 | 4 |
Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.
| Participants | Part A: Ruxolitinib Cream |
|---|---|
| Week 4 | 0 |
| Week 8 | 0 |
| Week 12 | 3 |
| Week 18 | 4 |
| Week 24 | 6 |
Percentage of subjects achieving a SALT 50 (defined as a ≥ 50% improvement from baseline in SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss.
| Participants | Part B : Placebo Cream | Part B: Ruxolitinib Cream |
|---|---|---|
| Part B : Percentage of Participants Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented) | 5 | 5 |
Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.
| Participants | Part A: Ruxolitinib Cream |
|---|---|
| Week 4 | 0 |
| Week 8 | 0 |
| Week 12 | 2 |
| Week 18 | 3 |
| Week 24 | 4 |
Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.
| Participants | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|
| Part B : Percentage of Participants With 50% to 100% Scalp Involvement at Baseline Achieving a SALT50 Response in Terminal Hair (Pigmented and Nonpigmented). | 2 | 4 |
Number of participants achieving 90% or greater improvement in their SALT score (SALT90) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes.
| Participants | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|---|
| Week4 | 0 | 0 | 0 |
| Week 8 | 0 | 0 | 0 |
| Week 12 | 0 | 0 | 1 |
| Week 18 | 1 | 0 | 2 |
| Week 24 | 2 | 0 | 2 |
Number of subjects achieving a Physician's Global Assessment (PGA) score of 3 or above at week 24 (0, no regrowth; 1, \<25% of regrowth; 2, 25%-49% of regrowth; 3, 50%-74% of regrowth; 4, 75%-99% of re- growth; 5, 100% of regrowth).
| Participants | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|
| Part B : Percentage of Subjects Whose AA Lesions Treated Since Baseline Achieved a Physician's Global Assessment of Regrowth (PGARG) Score of at Least 3 | 5 | 2 |
Number of participants achieving 50% or greater improvement in their SALT score (SALT50) compared to Baseline. SALT score 0-100 with lower score indicating better health outcomes
| Participants | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|
| Week 4 | 0 | 0 |
| Week 8 | 0 | 2 |
| Week 12 | 1 | 3 |
| Week 18 | 4 | 5 |
Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).
| Units on a Scale | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|
| Change from Baseline to Week 4 | 1.02 ± 1.577 | 0.13 ± 1.534 |
| Change from Baseline to Week 8 | 2.13 ± 2.233 | -1.11 ± 2.160 |
| Change from Baseline to Week 12 | 1.23 ± 2.956 | -2.55 ± 2.873 |
| Change from Baseline to Week 18 | -0.01 ± 3.550 | -4.16 ± 3.461 |
| Change from Baseline to Week 24 | -1.68 ± 3.886 | -3.92 ± 3.794 |
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment
| Participants | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream |
|---|---|---|---|
| Treatment Period | 9 | 28 | 23 |
| Extension Period | 7 | 23 | 22 |
Collected over Up to 100 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Cream | 0/38 (0%) | 0/38 (0%) | 14/38 (36.8%) |
| Ruxolitinib Cream | 0/83 (0%) | 4/83 (4.8%) | 31/83 (37.3%) |
| Event | Placebo Cream | Ruxolitinib Cream |
|---|---|---|
| DiverticulitisInfections and infestations | 0/38 | 1/83 |
| Generalised anxiety disorderPsychiatric disorders | 0/38 | 1/83 |
| Infected neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/38 | 1/83 |
| Lentigo malignaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/38 | 1/83 |
| Non-cardiac chest painGeneral disorders | 0/38 | 1/83 |
| SepsisInfections and infestations | 0/38 | 1/83 |
| Event | Placebo Cream | Ruxolitinib Cream |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/38 | 13/83 |
| PruritusSkin and subcutaneous tissue disorders | 3/38 | 10/83 |
| SinusitisInfections and infestations | 1/38 | 7/83 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 3/38 | 3/83 |
| Urinary tract infectionInfections and infestations | 0/38 | 5/83 |
| BronchitisInfections and infestations | 2/38 | 2/83 |
| Age, Continuous(Years) | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream | Total |
|---|---|---|---|---|
| Mean | 47.6 ± 13.17 | 44.3 ± 15.92 | 42.4 ± 14.69 | 43.4 ± 15.25 |
| Sex: Female, Male(Participants) | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream | Total |
|---|---|---|---|---|
| Female | 9 | 24 | 27 | 60 |
| Male | 3 | 15 | 12 | 30 |
| Race/Ethnicity, Customized(Participants) | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream | Total |
|---|---|---|---|---|
| White or Caucasian | 11 | 33 | 29 | 73 |
| Black or African American | 0 | 5 | 4 | 9 |
| Asian | 1 | 1 | 0 | 2 |
| Other | 0 | 0 | 5 | 5 |
| Unknown | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Part A: Ruxolitinib Cream | Part B : Placebo Cream | Part B : Ruxolitinib Cream | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 5 | 9 |
| Not Hispanic or Latino | 11 | 36 | 33 | 80 |
| Not Reported | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2015 to primary completion in Oct 2017, 22 months.
Results were first posted in Dec 2020, 3 years 2 months after primary completion. A results delay was requested in Oct 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib